Metastatic Renal Cell Carcinoma Clinical Trial
Official title:
Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)
- Retrospective studies showed Sorafenib's efficacy as second line treatment after a
Tyrosine Kinase Inhibitor (TKI).
- Currently there is no standard of treatment in 2nd line for patients treated in first
line with pazopanib for metastatic Renal Cell Carcinoma (mRCC).
- With this trial we evaluate the efficacy of sorafenib as second line of treatment in
patients treated with pazopanib for mRCC.
- Retrospective studies showed Sorafenib's efficacy as second line treatment after a TKI:
AXIS study showed sorafenib activity, in terms of Overall Response Rate (ORR), and the
absence statistically significant difference in Overall Survival (OS) between the 2
arms, although there is a significant OS increase of 1.4 months in the Axitinib arm. The
INTORSECT study (temsirolimus vs sorafenib in 2nd line after sunitinib) didn't
demonstrate statistically significant difference for Progression Free Survival (PFS),
but it showed an OS increase in patients treated with sorafenib.
- The COMPARZ study demonstrated the non-inferiority of pazopanib vs sunitinib in 1st line
of treatment for mRCC.
- Currently there is no standard of treatment in 2nd line for patients treated in first
line with pazopanib for mRCC.
- Primary objective:to evaluate the efficacy of sorafenib (PFS) as second line of
treatment in patients treated with pazopanib for mRCC.
- Secondary objectives: To evaluate the safety of sorafenib in patients previously treated
with pazopanib. To evaluate the Overall Survival. To evaluate the Quality of Life
through specific questionnaires (FKSI-19; European Organization for Research and
Treatment of Cancer quality of life questionnaire -C30).To assess the predictive role
for PFS and OS of arterial blood pressure increase from baseline to week 4 and 8 after
start of treatment with sorafenib. To assess the predictive role for PFS and OS of
hand-foot syndrome before week 4 and 8 after start of treatment with sorafenib.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00930033 -
Clinical Trial to Assess the Importance of Nephrectomy
|
Phase 3 | |
| Recruiting |
NCT05863351 -
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
|
Phase 3 | |
| Not yet recruiting |
NCT06284564 -
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
|
Phase 2 | |
| Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
| Active, not recruiting |
NCT03149822 -
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03647878 -
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
|
||
| Completed |
NCT01517243 -
Phase II Study of Alternating Sunitinib and Temsirolimus
|
Phase 2 | |
| Withdrawn |
NCT03927248 -
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01182142 -
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
|
Phase 2 | |
| Completed |
NCT00630409 -
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT04076787 -
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
|
||
| Active, not recruiting |
NCT04467021 -
Cancer and Blood Pressure Management, CARISMA Study
|
N/A | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02282579 -
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
|
||
| Terminated |
NCT02071641 -
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01731158 -
Sequential Therapy in Metastatic Renal Cell Carinoma
|
Phase 2 | |
| Terminated |
NCT01342627 -
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT01274273 -
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
|
Phase 2 | |
| Completed |
NCT00848640 -
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 |